BridgeMD
New treatment option for EGFR
Official title Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
ClinicalTrials.gov ID: NCT06755684
What this study is testing
What is Befotertinib combined Bevacizumab?
Befotertinib combined Bevacizumab is an investigational medicine, being studied as a potential treatment for egfr.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;
- At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS;
- No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);
- With the feasibility to receive radical surgery ;
- Good lung function that could tolerate surgical treatment;
You likely can't join if
- The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment...
- The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina...
- The patient is a carrier of HIV;
- The patient has had or is currently suffering from interstitial lung disease;
- The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;
- The patient is allergic to befotertinib or its any excipients;
See the full eligibility criteria
- NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;
- At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS;
- No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);
- With the feasibility to receive radical surgery ;
- Good lung function that could tolerate surgical treatment;
- Aged 18-75 years;
- At least one measurable tumor foci (the longest diameter measured by CT shall be \> 10 mm);
- Other major organs shall function well (liver, kidney, blood system, etc.):
- ECOG PS score shall be 0-1;
- The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and...
- The patient shall sign the Informed Consent Form.
- The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;
- The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart...
- The patient is a carrier of HIV;
- The patient has had or is currently suffering from interstitial lung disease;
- The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;
- The patient is allergic to befotertinib or its any excipients;
- The patient is allergic to bevacizumab or its any excipients;
- The patient is allergic to platinum-based double chemotherapy or its any excipients;
- The female patient is in pregnancy or lactation period;
- There are any conditions under which the investigator considers the patient is not suitable to be enrolled.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.